These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29848120)

  • 21. Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-α antagonist therapy.
    Singanayagam A; Manalan K; Sridhar S; Molyneaux PL; Connell DW; George PM; Kindelerer A; Seneviratne S; Lalvani A; Wickremasinghe M; Kon OM
    Thorax; 2013 Oct; 68(10):955-61. PubMed ID: 23976779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting.
    Conti A; Piaserico S; Gisondi P; Odorici G; Galdo G; Lasagni C; Pellacani G
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28547750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
    Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
    Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence.
    Kisacik B; Pamuk ON; Onat AM; Erer SB; Hatemi G; Ozguler Y; Pehlivan Y; Kilic L; Ertenli I; Can M; Direskeneli H; Keser G; Oksel F; Dalkilic E; Yilmaz S; Pay S; Balkarli A; Cobankara V; Cetin GY; Sayarlioglu M; Cefle A; Yazici A; Avci AB; Terzioglu E; Ozbek S; Akar S; Gul A
    J Rheumatol; 2016 Mar; 43(3):524-9. PubMed ID: 26773107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.
    Kurt OK; Kurt B; Talay F; Tug T; Soy M; Bes C; Hayran M
    Wien Klin Wochenschr; 2013 Oct; 125(19-20):616-20. PubMed ID: 24061693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment.
    Cantini F; Prignano F; Goletti D
    J Rheumatol Suppl; 2014 May; 91():78-82. PubMed ID: 24789004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden.
    Shin A; Lee YJ; Lee EB; Song YW; Kim SC; Kang EH
    Rheumatology (Oxford); 2021 Jun; 60(6):2755-2764. PubMed ID: 33188421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents.
    Klein M; Jarosová K; Forejtová S; Bečvář R; Sedová L; Pavelka K; Simková G; Svobodová R; Hviscová K; Mann H; Půtová I; Vencovský J
    Clin Exp Rheumatol; 2013; 31(1):111-7. PubMed ID: 23101473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspective.
    To KW; Reino JJ; Yoo DH; Tam LS
    Respirology; 2013 Jul; 18(5):765-73. PubMed ID: 23627398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].
    Diel R; Hauer B; Loddenkemper R; Manger B; Krüger K
    Pneumologie; 2009 Jun; 63(6):329-34. PubMed ID: 19517358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area.
    Bonfiglioli KR; Ribeiro AC; Moraes JC; Saad CG; Souza FH; Calich AL; Bonfa E; Laurindo IM
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):905-11. PubMed ID: 25199003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
    Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
    J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TST, QuantiFERON-TB Gold test and T-SPOT.TB test for detecting latent tuberculosis infection in patients with rheumatic disease prior to anti-TNF therapy.
    Sargın G; Şentürk T; Ceylan E; Telli M; Çildağ S; Doğan H
    Tuberk Toraks; 2018 Jun; 66(2):136-143. PubMed ID: 30246657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
    Cantini F; Niccoli L; Goletti D
    J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for latent tuberculosis in anti-TNF-α candidate patients in a high tuberculosis incidence setting.
    Saidenberg-Kermanac'h N; Semerano L; Naccache JM; Brauner M; Falgarone G; Dumont-Fischer D; Guillot X; Valeyre D; Boissier MC
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1307-14. PubMed ID: 22863801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
    Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tuberculosis screening prior to anti-tumor necrosis factor therapy among patients with immune-mediated inflammatory diseases in Japan: a longitudinal study using a large-scale health insurance claims database.
    Tomio J; Yamana H; Matsui H; Yamashita H; Yoshiyama T; Yasunaga H
    Int J Rheum Dis; 2017 Nov; 20(11):1674-1683. PubMed ID: 29076252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.
    Lee H; Park HY; Jeon K; Jeong BH; Hwang JW; Lee J; Cha HS; Koh EM; Kang ES; Koh WJ
    PLoS One; 2015; 10(3):e0119260. PubMed ID: 25746854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapy.
    He D; Bai F; Zhang S; Jiang T; Shen J; Zhu Q; Yue T; Shao L; Gao Y; Feng Y; Weng X; Zou H; Zhang Y; Zhang W
    Clin Vaccine Immunol; 2013 Jun; 20(6):842-7. PubMed ID: 23554465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
    Hsia EC; Schluger N; Cush JJ; Chaisson RE; Matteson EL; Xu S; Beutler A; Doyle MK; Hsu B; Rahman MU
    Arthritis Rheum; 2012 Jul; 64(7):2068-77. PubMed ID: 22238071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.